Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase Ib trial tests the safety, side effects, and best dose of M1774 when given with ZEN-3694 in treating patients with ovarian and endometrial cancer that has come back (recurrent). M1774 and ZEN-3694 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. M1774 and ZEN-3694 combined together has demonstrated to be better than either drug alone in killing ovarian tumor cells.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjentki z potwierdzonym laboratoryjnie nawrotowym rakiem jajnika lub macicy, który powrócił po leczeniu.
- •Wiek 18 lat lub więcej.
- •Ogólny stan zdrowia pozwalający na udział w badaniu (określany według skali ECOG do 2 punktów).
- •Leczone wcześniej maksymalnie 1-3 terapiami chemioterapeutycznymi.
✗ Disqualifies
- •Pacjentki, u których choroba postępuje w ciągu 6 miesięcy od zakończenia leczenia lekami zawierającymi platynę (w przypadku raka jajnika o wysokim stopniu złośliwości).
- •Pacjentki z rakiem macicy, które kwalifikują się do leczenia z intencją wyleczenia lub odmawiają takiego leczenia.
- •Brak danych dotyczących specyficznych typów nowotworów (np. raka macicy z określonym stopniem FIGO).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- June 29, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (14)
Augusta University Medical Center
Augusta, United States
University of Chicago Comprehensive Cancer Center
Chicago, United States
University of Iowa/Holden Comprehensive Cancer Center
Iowa City, United States
Wayne State University/Karmanos Cancer Institute
Detroit, United States
University of New Mexico Cancer Center
Albuquerque, United States
Case Western Reserve University
Cleveland, United States
Cleveland Clinic Foundation
Cleveland, United States
Ohio State University Comprehensive Cancer Center
Columbus, United States
University of Oklahoma Health Sciences Center
Oklahoma City, United States
NRG Oncology
Philadelphia, United States
University of Pennsylvania/Abramson Cancer Center
Philadelphia, United States
Thomas Jefferson University Hospital
Philadelphia, United States
Women and Infants Hospital
Providence, United States
Medical College of Wisconsin
Milwaukee, United States
Trial contact
Site Public Contact
Katherine C. Kurnit
PRINCIPAL_INVESTIGATOR
Site Public Contact
David P. Bender
PRINCIPAL_INVESTIGATOR
Site Public Contact
Ira S. Winer
PRINCIPAL_INVESTIGATOR
Site Public Contact
Carolyn Y. Muller
PRINCIPAL_INVESTIGATOR
Site Public Contact
Peter G. Rose
PRINCIPAL_INVESTIGATOR
Site Public Contact
John L. Hays
PRINCIPAL_INVESTIGATOR
Site Public Contact
Lauren E. Dockery
PRINCIPAL_INVESTIGATOR
Fiona Simpkins
Fiona Simpkins
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Mitchell I. Edelson
PRINCIPAL_INVESTIGATOR
Site Public Contact
Cara A. Mathews
PRINCIPAL_INVESTIGATOR
Site Public Contact
William H. Bradley
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.